Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014-Reference-Cited by-同舟云学术

Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014

Published:2014-07-31 Issue:30 Volume:19 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Golparian D¹,Ohlsson A K²,Janson H³,Lidbrink P⁴,Richtner T⁵,Ekelund O³,Fredlund H¹,Unemo M¹

Affiliation:

1. World Health Organization Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden

2. Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden

3. Department of Clinical Microbiology, Central Hospital, Växjö, Sweden

4. Department of Dermatovenereology, Karolinska University Hospital, Stockholm, Sweden

5. Department of Dermatology, Karolinska Institutet at Södersjukhuset, Stockholm, Sweden

Abstract

We describe four cases in Sweden of verified treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg; n=3) or cefotaxime (500 mg; n=1) monotherapy. All the ceftriaxone treatment failures were caused by the internationally spreading multidrug-resistant gonococcal NG-MAST genogroup 1407 clone. Increased awareness of treatment failures is crucial particularly when antimicrobial monotherapy is used. Frequent test of cure and appropriate verification/falsification of suspected treatment failures, as well as implementation of recommended dual antimicrobial therapy are imperative.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference21 articles.

1. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

2. Meeting the public health challenge of multidrug- and extensively drug-resistantNeisseria gonorrhoeae

3. The Gonococcus fights back: is this time a knock out?

4. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea

5. Neisseria gonorrhoeae Treatment Failure and Susceptibility to Cefixime in Toronto, Canada

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Neisseria gonorrhoeae infection: from drug resistance to drug repurposing;Expert Opinion on Therapeutic Patents;2024-06-02

2. Challenges in Managing Gonorrhea and New Advances in Prevention;Infectious Disease Clinics of North America;2023-06

3. Multidrug-resistant Neisseria gonorrhoeae isolate SE690: mosaic penA-60.001 gene causing ceftriaxone resistance internationally has spread to the more antimicrobial-susceptible genomic lineage, Sweden, September 2022;Eurosurveillance;2023-03-09

4. Current Susceptibility Surveillance and Distribution of Antimicrobial Resistance in N. gonorrheae within WHO Regions;Pathogens;2022-10-25

5. In vitro Susceptibility to β-Lactam Antibiotics and Viability of Neisseria gonorrhoeae Strains Producing Plasmid-Mediated Broad- and Extended-Spectrum β-Lactamases;Frontiers in Microbiology;2022-06-20